/ONC.TO
ONC.TO Stock - Oncolytics Biotech Inc.
Healthcare|BiotechnologyTSX
$1.42+2.16%
+$0.03 (+2.16%) • Aug 22
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.96
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.56
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ONC.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.41 – $1.43
TARGET (TP)$1.63
STOP LOSS$1.31
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.48
52W High$2.08
52W Low$0.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-424,000 | $-403,000 | $-392,000 | $-452,065 | $-446,187 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-34,982,000 | $-33,791,000 | $-28,569,000 | $-26,234,945 | $-25,459,006 |
| Net Income | $-31,710,000 | $-27,752,000 | $-24,835,000 | $-26,304,279 | $-19,551,108 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.41 | $-0.41 | $-0.43 | $-0.49 | $-0.48 |
Company Overview
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ONC.TOBeat Rate
53%
Last 17 quarters
Avg Surprise
+6.5%
EPS vs Estimate
Beats / Misses
9/7
1 met exactly
Latest EPS
$-0.07
Q3 2025
EPS Surprise History
Q4 23
-40.0%
$-0.14vs$-0.10
Q1 24
+66.7%
$-0.05vs$-0.15
Q2 24
+18.2%
$-0.09vs$-0.11
Q3 24
0.0%
$-0.10vs$-0.10
Q4 24
-20.0%
$-0.12vs$-0.10
Q1 25
+16.7%
$-0.10vs$-0.12
Q2 25
+20.0%
$-0.08vs$-0.10
Q3 25
-0.7%
$-0.07vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 8, 2025 | $-0.07 | $-0.07 | -0.7% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q1 2025 | Mar 5, 2025 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.10 | $-0.12 | -20.0% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.10 | $-0.10 | 0.0% | = MET |
Q2 2024 | May 9, 2024 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q1 2024 | Mar 7, 2024 | $-0.15 | $-0.05 | +66.7% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.10 | $-0.14 | -40.0% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.11 | $-0.12 | -9.1% | ✗ MISS |
Q2 2023 | May 5, 2023 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q1 2023 | Mar 3, 2023 | $-0.10 | $-0.15 | -50.0% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.11 | $-0.08 | +27.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | $-0.14 | $-0.09 | +35.7% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $-0.12 | $-0.13 | -8.3% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ONC.TO
What is ONC.TO's current stock price?
Oncolytics Biotech Inc. (ONC.TO) is currently trading at $1.42 per share. The stock has moved +2.16% today.
What is the analyst price target for ONC.TO?
No analyst price targets are currently available for this stock.
What sector is Oncolytics Biotech Inc. in?
Oncolytics Biotech Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.
What is ONC.TO's market cap?
Oncolytics Biotech Inc. has a market capitalization of $0.14 billion, making it a small-cap company.
Does ONC.TO pay dividends?
No, Oncolytics Biotech Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAEZS.TO
Aeterna Zentaris Inc.
$8.29
Mkt Cap: $0.0B
BHSC.CN
BioHarvest Sciences Inc.
$7.95
Mkt Cap: $0.1B
GDNS.CN
Goodness Growth Holdings, Inc.
$0.63
Mkt Cap: $0.1B
IGX.TO
IntelGenx Technologies Corp.
$0.24
Mkt Cap: $0.0B
MSCL.V
Satellos Bioscience Inc.
$0.56
Mkt Cap: $0.1B
MSET.CN
Mindset Pharma Inc.
$0.74
Mkt Cap: $0.1B
NVCN.TO
Neovasc Inc.
$40.15
Mkt Cap: $0.1B
PMN.TO
ProMIS Neurosciences, Inc.
$6.00
Mkt Cap: $0.1B
SBBC.V
Simply Better Brands Corp.
$0.92
Mkt Cap: $0.1B
TMD.TO
Titan Medical Inc.
$1.13
Mkt Cap: $0.1B
Explore stocks similar to ONC.TO for comparison